B. Riley Financial Boosts KindlyMD (NASDAQ:NAKA) Price Target to $13.00

Key Points

• B. Riley Financial raised KindlyMD’s price target from $11 to $13 and maintained a “buy” rating, implying 31.18% upside from the stock’s $9.91 trading price.
• Analyst sentiment remains mixed: three analysts rate the stock “buy,” while others assign “hold” and “sell” ratings; the consensus rating is “Hold” with a $20 price target.
• KindlyMD reported a $6.65 per-share quarterly loss on $35.87 million in revenue, alongside sharply negative margins. CEO David Bailey and other insiders purchased 41,904 shares worth approximately $235,000 over the past 90 days.

KindlyMD (NASDAQ:NAKA - Get Free Report) had its target price upped by equities research analysts at B. Riley Financial from $11.00 to $13.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. B. Riley Financial's target price points to a potential upside of 31.18% from the stock's current price.

NAKA has been the topic of several other research reports. TD Cowen boosted their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Weiss Ratings restated a "sell (d-)" rating on shares of KindlyMD in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $20.00.

KindlyMD Price Performance

NASDAQ:NAKA traded down $0.14 during trading hours on Tuesday, hitting $9.91. The company had a trading volume of 174,961 shares, compared to its average volume of 200,416. The company has a market capitalization of $177.39 million, a PE ratio of -0.28 and a beta of 15.99. The stock has a 50-day moving average price of $6.20 and a 200 day moving average price of $6.78. KindlyMD has a 52 week low of $3.33 and a 52 week high of $53.20.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The company had revenue of $35.87 million for the quarter. Analysts anticipate that KindlyMD will post -12.87 EPS for the current fiscal year.

Insider Transactions at KindlyMD

In other news, CEO David F. Bailey acquired 32,134 shares of the stock in a transaction on Wednesday, August 19th. The stock was acquired at an average price of $5.59 per share, with a total value of $179,629.06. Following the completion of the transaction, the chief executive officer owned 32,134 shares of the company's stock, valued at $179,629.06. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 41,904 shares of company stock valued at $235,231 in the last ninety days. 24.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NAKA. Hunting Hill Global Capital LLC bought a new position in shares of KindlyMD during the fourth quarter valued at approximately $4,672,000. Yorkville Advisors Global LP bought a new stake in KindlyMD in the fourth quarter worth $3,265,000. UBS Group AG bought a new stake in KindlyMD in the fourth quarter worth $2,958,000. Arrington Capital Management LLC purchased a new stake in shares of KindlyMD in the fourth quarter worth $1,028,000. Finally, Waddell & Associates LLC purchased a new stake in shares of KindlyMD in the fourth quarter worth $201,000.

About KindlyMD

KindlyMD, Inc is a healthcare company focused on providing integrated care for patients with complex medical needs, including chronic pain and substance use disorders. Its care model combines primary care, behavioral health services and medication-assisted treatment, with an emphasis on coordinated, patient-centered treatment.

The company has operated clinics in Utah and has also used telehealth and other technology-enabled services to expand access to care. KindlyMD's services are designed to support patients through ongoing treatment and recovery rather than addressing individual medical issues in isolation.

KindlyMD became a publicly traded company through a business combination involving Nakamoto Holdings, with its common stock trading on the Nasdaq under the symbol NAKA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.